Other languages Johnson & Johnson Wiener Boerse

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 01:56:25 01/07/2024 pm IST			5-day change	1st Jan Change
136.3 ^EUR	-0.46%		-1.43%	-3.39%

28/06	Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	MT
28/06	J&J Unit's Rybrevant Combo Gets EU Approval	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Momentum Picks T3 2024 : 5 actions pour l'été	01:13pm
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	11:54am
Nouveau semestre, nouvel état d'esprit	11:42am
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	11:30am
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	28/06
J&J Unit's Rybrevant Combo Gets EU Approval	28/06
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	28/06
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	28/06
Dealmakers optimistic on global M&A prospects despite sluggish growth	28/06
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	24/06
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06
Johnson & Johnson : dossier déposé dans la maladie de Crohn	21/06
Johnson & Johnson : le rachat de Proteologix est bouclé	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	21/06
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	21/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST